Latest news with #AscendisPharma
Yahoo
05-05-2025
- Business
- Yahoo
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen. Four oral presentations will feature Ascendis clinical trial results, including 4-year efficacy and safety data from the Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with chronic hypoparathyroidism; Week 52 growth and bone morphometry data from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia; and efficacy and safety data from the Phase 3 foresiGHt Trial of TransCon hGH (lonapegsomatropin) in adults with growth hormone deficiency. 'As new treatments and clinical practices transform the outlook for rare endocrine diseases, we are pleased to partner with trial investigators and leading experts to share new data highlighting clinical benefits of our novel therapies with attendees of ESPE & ESE 2025,' said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma. The full range of Ascendis Pharma events and updates at ESPE & ESE 2025 include the following: Hypoparathyroidism Sunday, May 1109:55 - 10:25 CEST Congress TheaterFoyer F5 Product TheaterRestoring Physiological Levels of PTH in Chronic HypoparathyroidismClick here to see the full session outline. Sunday, May 1116:55-17-55 CEST& Monday, May 1217:15-17:45 CESTPoster Hall Poster P238Estimating the Risk of Chronic Kidney Disease Progression in Chronic Hypoparathyroidism: A Restrospective Matched Cohort Study, Using Real-World Data from England Monday, May 1213:00 - 14:30 CESTRoom D5 SymposiumBeyond Conventional Care: Redefining Treatment Success in Chronic HypoparathyroidismClick here to see the full session outline. Monday, May 1215:55-16:05 CESTRoom C2 Oral PresentationLong-Term Efficacy & Safety of Palopegteriparatide Treatment in Adults with Chronic Hypoparathyroidism: 4-Year Results from the Phase 2 PaTH Forward TrialPresented by Dr. Andrea Palermo Achondroplasia Sunday, May 1115:55-17:25 CESTRoom C2 SymposiumAssessing HRQoL in Achondroplasia Across the Life CourseClick here to see the full session outline. Monday, May 1215:15-15:25 CESTRoom C2 Oral PresentationEffects of Navepegritide on Bone Morphometry in Children with Achondroplasia: 52-Week Results from the ApproaCH Clinical TrialPresented by Dr. Leanne Ward Tuesday, May 1315:05-15:15 CESTRoom D2 Oral PresentationEffects of Navepegritide on Growth in Children with Achondroplasia: 52-Week Results from the ApproaCH Clinical TrialPresented by Dr. Hanne Hove Growth Hormone Deficiency Tuesday, May 1314:45-14:55 CESTRoom D2 Oral PresentationResults of the foresiGH Trial Support the Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults with Growth Hormone Deficiency (GHD)Presented by Dr. Aleksandra Gilis-Januszewska More information about the events and presentations listed here is available to registered attendees of the Joint ESPE & ESE 2025 congress. About HypoparathyroidismHypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes. About AchondroplasiaAchondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal deformities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can have detrimental effects on quality of life, physical functioning, and psychosocial function. Individuals with achondroplasia often require multiple surgeries and procedures to alleviate the condition's many complications. About Adult Growth Hormone DeficiencyGrowth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual's body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the clinical benefits of Ascendis' novel therapies, (ii) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients, and (iii) Ascendis' application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, and TransCon are trademarks owned by the Ascendis Pharma group. © May 2025 Ascendis Pharma A/ Contacts: Scott Smith Ascendis Pharma ir@ Media Contact:Melinda BakerAscendis Pharmamedia@ BankICR Healthcare+1 (415) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients and (ii) Ascendis' application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © April 2025 Ascendis Pharma A/S. Investor Contacts: Media Contact: Scott Smith Melinda Baker Ascendis Pharma Ascendis Pharma ir@ media@ Patti Bank ICR Healthcare +1 (415) 513-1284
Yahoo
14-04-2025
- Business
- Yahoo
High Growth Tech Stocks In US With Potential For Expansion
The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 20.44% 29.79% ★★★★★★ Arcutis Biotherapeutics 25.76% 58.17% ★★★★★★ TG Therapeutics 26.03% 37.60% ★★★★★★ Alkami Technology 20.46% 85.16% ★★★★★★ Travere Therapeutics 28.65% 65.75% ★★★★★★ Alnylam Pharmaceuticals 22.74% 58.77% ★★★★★★ TKO Group Holdings 22.48% 25.17% ★★★★★★ AVITA Medical 28.22% 55.77% ★★★★★★ Lumentum Holdings 21.61% 120.49% ★★★★★★ Ascendis Pharma 32.36% 59.79% ★★★★★★ Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Growth Rating: ★★★★★★ Overview: Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference with a market cap of approximately $30.78 billion. Operations: Alnylam generates revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.25 billion. The company operates within the biotechnology sector with a focus on innovative therapeutic solutions. Alnylam Pharmaceuticals has demonstrated a robust commitment to innovation, particularly through its recent FDA approval of AMVUTTRA for ATTR-CM and Qfitlia for hemophilia. These approvals not only enhance its product portfolio but also underscore its R&D capabilities, reflected in a significant 22.7% annual revenue growth. The company's strategic presentations at various healthcare conferences, coupled with the launch of groundbreaking RNAi therapeutics like vutrisiran, show a clear trajectory towards addressing critical unmet medical needs. Despite being unprofitable currently, Alnylam's projected earnings growth of 58.77% annually suggests potential for future profitability and leadership in the biotech sector. Navigate through the intricacies of Alnylam Pharmaceuticals with our comprehensive health report here. Examine Alnylam Pharmaceuticals' past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★★ Overview: Ascendis Pharma A/S is a biopharmaceutical company specializing in the development of TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and globally, with a market cap of approximately $9.04 billion. Operations: Ascendis Pharma generates revenue primarily from its biotechnology segment, amounting to €363.64 million. The company is focused on developing TransCon-based therapies to address unmet medical needs across various regions. Ascendis Pharma is navigating a transformative phase with its recent NDA submission for TransCon CNP, targeting achondroplasia treatment, reflecting its commitment to addressing rare diseases through innovative drug development. Despite being unprofitable, the company's revenue is projected to grow at 32.4% annually, outpacing the US market average of 8.3%. With R&D expenses aligning closely with these ambitious projects, Ascendis also announced a share repurchase program valued at $18.25 million, signaling confidence in its future financial health. This strategic mix of product development and financial maneuvers positions Ascendis uniquely within the biotech landscape as it transitions towards profitability forecasted with an impressive annual earnings growth rate of 59.79%. Get an in-depth perspective on Ascendis Pharma's performance by reading our health report here. Explore historical data to track Ascendis Pharma's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Natera, Inc. is a diagnostics company that offers molecular testing services globally, with a market cap of approximately $20.01 billion. Operations: The company generates revenue primarily from the development and commercialization of molecular testing services, totaling approximately $1.70 billion. Natera, a player in the genetic testing and diagnostics sector, is steering through a dynamic phase marked by strategic board expansions and intriguing clinical trials. With a revenue leap to $1.87 billion forecasted for 2025, the company's financial trajectory reflects vigorous growth, notably outpacing broader market trends. Recent R&D initiatives like the HEROES trial underscore Natera's commitment to pioneering in oncological research, potentially reshaping therapeutic approaches in cancer care. Moreover, the adoption of its Signatera test for Medicare coverage marks a significant milestone, enhancing its standing in precision medicine and boosting its commercial prospects amidst competitive pressures. Unlock comprehensive insights into our analysis of Natera stock in this health report. Review our historical performance report to gain insights into Natera's's past performance. Embark on your investment journey to our 232 US High Growth Tech and AI Stocks selection here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ALNY NasdaqGS:ASND and NasdaqGS:NTRA. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Globe and Mail
11-04-2025
- Health
- Globe and Mail
Hypopituitarism Market on Track for Major Expansion by 2032, According to DelveInsight
The Key Hypopituitarism Companies in the market include - Ascendis Pharma, Lumos Pharma, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., AbbVie, Novo Nordisk, Sanofi, AstraZeneca, Teva Pharmaceutical Industries, Ferring Pharmaceuticals, and others. DelveInsight's 'Hypopituitarism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypopituitarism, historical and forecasted epidemiology as well as the Hypopituitarism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Some of the key facts of the Hypopituitarism Market Report: The Hypopituitarism market size is anticipated to grow with a significant CAGR during the study period (2019-2032) In December 2024, OPDIVO QVANTIG may lead to primary or secondary adrenal insufficiency, immune-related hypophysitis, immune-mediated thyroid conditions, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Depending on the severity, OPDIVO QVANTIG should be withheld [refer to section 2 Dosage and Administration in the Full Prescribing Information]. For Grade 2 or higher adrenal insufficiency, initiate appropriate symptomatic management, including hormone replacement therapy if needed. Hypophysitis may manifest with acute symptoms like headaches, sensitivity to light, or vision disturbances due to mass effect. It may also result in hypopituitarism, requiring hormone replacement as clinically appropriate. Hypopituitarism is anticipated to have a global incidence rate of 4.2 cases per 100,000 people annually, with a prevalence of 45.5 cases per 100,000, showing no distinction between genders. The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric patients aged one year and older who weigh at least 11.5 kg and have growth failure as a result of insufficient endogenous growth hormone secretion The study by Rogol stated that GHD in children is a relatively rare condition. In the United States, it was estimated to occur in approximately 1 in 3500 to 4000 children As per National Institute for Health and Clinical Excellence (NICE), the prevalence of growth hormone deficiency was estimated to be between 1 in 3500 and 1 in 4000 children In about half of the children with growth hormone deficiency (50%), the cause is unknown (idiopathic growth hormone deficiency) Key Hypopituitarism Companies: Ascendis Pharma, Lumos Pharma, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., AbbVie, Novo Nordisk, Sanofi, AstraZeneca, Teva Pharmaceutical Industries, Ferring Pharmaceuticals, and others Key Hypopituitarism Therapies: Lonapegsomatropin, LUM-201, somapacita, and others The Hypopituitarism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypopituitarism pipeline products will significantly revolutionize the Hypopituitarism market dynamics. Hypopituitarism Overview: Hypopituitarism is a rare disorder in which the pituitary gland, located at the base of the brain, fails to produce one or more of its hormones or produces them in insufficient amounts. These hormones regulate essential functions such as growth, reproduction, and metabolism. Causes of hypopituitarism can include tumors, head injuries, infections, or autoimmune conditions. Symptoms vary depending on which hormones are deficient and may include fatigue, weakness, weight loss, infertility, and growth problems. Treatment usually involves hormone replacement therapy to restore normal body functions. Hypopituitarism Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Hypopituitarism Epidemiology Segmentation: The Hypopituitarism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Download the report to understand which factors are driving Hypopituitarism epidemiology trends @ Hypopituitarism Epidemiology Forecast Hypopituitarism Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypopituitarism market or expected to get launched during the study period. The analysis covers Hypopituitarism market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Hypopituitarism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Hypopituitarism Therapies and Key Companies Scope of the Hypopituitarism Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Hypopituitarism Companies: Ascendis Pharma, Lumos Pharma, Novartis, Pfizer, Eli Lilly and Company, Merck & Co., AbbVie, Novo Nordisk, Sanofi, AstraZeneca, Teva Pharmaceutical Industries, Ferring Pharmaceuticals, and others Key Hypopituitarism Therapies: Lonapegsomatropin, LUM-201, somapacitan, and others Hypopituitarism Therapeutic Assessment: Hypopituitarism current marketed and Hypopituitarism emerging therapies Hypopituitarism Market Dynamics: Hypopituitarism market drivers and Hypopituitarism market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Hypopituitarism Unmet Needs, KOL's views, Analyst's views, Hypopituitarism Market Access and Reimbursement To know more about Hypopituitarism companies working in the treatment market, visit @ Hypopituitarism Clinical Trials and Therapeutic Assessment Table of Contents 1. Hypopituitarism Market Report Introduction 2. Executive Summary 3. SWOT analysis 4. Hypopituitarism Patient Share (%) Overview at a Glance 5. Hypopituitarism Market Overview at a Glance 6. Hypopituitarism Disease Background and Overview 7. Hypopituitarism Epidemiology and Patient Population 8. Country-Specific Patient Population of Hypopituitarism 9. Hypopituitarism Current Treatment and Medical Practices 10. Hypopituitarism Unmet Needs 11. Hypopituitarism Emerging Therapies 12. Hypopituitarism Market Outlook 13. Country-Wise Hypopituitarism Market Analysis (2018–2030) 14. Market Access and Reimbursement of Therapies 15. Market drivers 16. Market barriers 17. Appendix 18. Hypopituitarism Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
03-03-2025
- Business
- Yahoo
Exploring US High Growth Tech Stocks In March 2025
Over the last 7 days, the United States market has experienced a slight decline of 1.3%, yet it has shown resilience with a 15% increase over the past year and earnings forecast to grow by 14% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to sustain growth amidst fluctuating market conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 25.26% 29.10% ★★★★★★ AsiaFIN Holdings 51.75% 82.69% ★★★★★★ Travere Therapeutics 28.43% 65.01% ★★★★★★ Alkami Technology 20.94% 85.17% ★★★★★★ AVITA Medical 27.78% 55.33% ★★★★★★ TG Therapeutics 29.48% 45.20% ★★★★★★ Clene 61.16% 59.11% ★★★★★★ Alnylam Pharmaceuticals 22.90% 58.64% ★★★★★★ Zai Lab 28.84% 67.49% ★★★★★★ Lumentum Holdings 21.24% 119.37% ★★★★★★ Click here to see the full list of 236 stocks from our US High Growth Tech and AI Stocks screener. Let's uncover some gems from our specialized screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases, with a market cap of $2.23 billion. Operations: Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases. As a clinical-stage biopharmaceutical company, it is currently not generating revenue from its operations. Soleno Therapeutics, despite its recent financial challenges marked by a net loss of $175.85 million for the year, remains a focal point in biotech due to its aggressive R&D initiatives and anticipated revenue growth. The company's strategic maneuvers, including a significant shelf registration of $82.25 million and securing a $200 million loan for advancing Prader-Willi syndrome treatments, underscore its commitment to innovation and market expansion. With an expected annual revenue increase of 49.4%, Soleno is positioning itself strategically within the high-growth biotech sector, aiming to leverage R&D breakthroughs into commercial success in the coming years. Dive into the specifics of Soleno Therapeutics here with our thorough health report. Learn about Soleno Therapeutics' historical performance. Simply Wall St Growth Rating: ★★★★★☆ Overview: Ascendis Pharma A/S is a biopharmaceutical company that develops TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and internationally, with a market cap of $9.37 billion. Operations: Ascendis Pharma generates revenue primarily from its biotechnology segment, amounting to €363.64 million. The company's focus is on developing therapies using its proprietary TransCon technology platform. Ascendis Pharma has demonstrated resilience and strategic foresight in the high-growth biotech landscape, marked by a notable 32.5% annual revenue growth and a reduction in net loss from EUR 481.45 million to EUR 378.08 million year-over-year. The company's recent shelf registration of $108 million underscores its proactive approach to funding future innovations, while its R&D commitment is evident from the substantial advancements in its TransCon technology platforms, promising enhanced treatment efficacy across multiple therapeutic areas. Moreover, Ascendis' recent share repurchase program highlights confidence in its financial health and future prospects, positioning it as a dynamic player amidst challenging market conditions and ongoing patent disputes with competitors like BioMarin. Get an in-depth perspective on Ascendis Pharma's performance by reading our health report here. Gain insights into Ascendis Pharma's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: ServiceNow, Inc. offers cloud-based solutions for digital workflows across various regions globally and has a market capitalization of $191.53 billion. Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $10.98 billion. ServiceNow, a leader in digital workflow solutions, is capitalizing on the AI-driven transformation across industries. With a robust 15.2% annual revenue growth and an impressive 20.6% forecast in earnings growth, the company is setting benchmarks in integrating AI to enhance operational efficiencies. Recently, ServiceNow introduced AI agents for telecoms, developed with NVIDIA's cutting-edge technology, aimed at automating complex customer service and network operations workflows. This innovation not only underscores ServiceNow's commitment to R&D (spending significant portions of its $10.98 billion revenue on these initiatives) but also positions it strategically within a sector poised for substantial growth due to AI adoption. Click to explore a detailed breakdown of our findings in ServiceNow's health report. Assess ServiceNow's past performance with our detailed historical performance reports. Investigate our full lineup of 236 US High Growth Tech and AI Stocks right here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqCM:SLNO NasdaqGS:ASND and NYSE:NOW. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
